Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.

April 11, 2025

Vol.51 No.14

By Claire Marie Porter

Clinical Roundup

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:

March 28, 2025

Vol.51 No.12

Drugs & Targets

EC expands approval for Breyanzi for r/r follicular lymphoma

The European Commission has granted approval to Breyanzi, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 21, 2025

Vol.51 No.11

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for HCC

The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

March 14, 2025

Vol.51 No.10

Drugs & Targets

FDA accepts sBLA for Opdivo + Yervoy in CRC

FDA accepted Bristol Myers Squibb’s supplemental biologics license application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

February 28, 2025

Vol.51 No.08

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

EC expands approval for Breyanzi for r/r follicular lymphoma

EC approves Opdivo + Yervoy as first-line treatment for HCC

FDA accepts sBLA for Opdivo + Yervoy in CRC

Renew today!

Subscriber content

Never miss an issue!

Login

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Only half of adolescents and young adults with cancer get fertility counseling before treatmentOncofertility consult is an oft-overlooked standard of care

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

EC expands approval for Breyanzi for r/r follicular lymphoma

EC approves Opdivo + Yervoy as first-line treatment for HCC

FDA accepts sBLA for Opdivo + Yervoy in CRC

Never miss an issue!

Login

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care